QUEBEC CITY, Dec. 13 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a leading developer of molecular diagnostics for the detection and management of cancer, announced a net loss from continuing operations of $1,718,318 or $0.05 per share for the quarter ending October 31, 2006, and a net loss from continuing operations of $6,491,586 or $0.19 per share for the fiscal year.
